Similar to the observations in mouse GC models, the relative amount of human tiNeus (CD11b+CD66b+) was also found to rapidly decrease with tumor progression (from 51.2% at stage I to 5.91% at stage IIIc) (Fig. 3E). This evidence concerns the gene CEACAM8 and neoplasm.